PMPushyami Mikkilineni

Pushyami Mikkilineni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pushyami Mikkilineni has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PSUN143 Perspectives of Patients Attending Endocrinology Clinic About COVID-19 Vaccination.

    by Pushyami Mikkilineni, Rebecca Simon, Arti Bhan, Sudhaker D Rao

    Introduction The outbreak of coronavirus disease 2019 (COVID-19) was initially detected in Wuhan, China in December 2019. It spread rapidly, and in March 2020, the World Health Organization (WHO) declared a worldwide pandemic. In May 2020, the 73rd World Health Assembly issued a resolution recognizing the role of extensive immunization as a global public-health goal for preventing and stopping transmission of COVID-19. Vaccine hesitancy is a great threat in fighting the COVID-19 pandemic, as it prevents populations from reaching target thresholds of coverage necessary for herd immunity. It is important to know the determinants of vaccine hesitancy so that we can develop tools to combat it. The goal of our study was to evaluate patient perspectives on vaccination in our outpatient Endocrinology clinics. Methods We created a 7-question survey study which was offered to all patients waiting to be seen in our three Endocrinology clinic locations. We distributed and collected data from all clinics over a 3-week period (5/31/21-6/18/21). We used descriptive statistics to analyze this data. Results We collected 446 responses between three clinic locations, one urban and two suburban. 361 patients (81%) reported planning to or already having received the COVID-19 vaccine. 29 patients (7%) reported being unsure and 56 patients (13%) reported they did not plan to get vaccinated. Among 85 patients with vaccine hesitancy, 51% are blacks, 35% are whites, 24% reported concerns related to side effects, 13% felt COVID was not as bad as the media portrays, 14% did not believe in vaccines and 29% wanted more data on side effects and efficacy before receiving it. Hesitancy is higher among blacks which is statistically significant (P = 0.035) and slightly higher at the urban compared to the suburban clinics (20% Vs. 15%; p=0.197). On chi square analysis, this had no significant difference. Discussion In the United States, COVID-19 vaccine acceptance ranged from 60 to 79% in five surveys among the general population. The rate of vaccination acceptance is higher in our study compared to general population. We suspect this is related to our clinic patients having better vaccine counseling as most patients have multiple risk factors for severe infection. The results did show higher vaccine hesitancy among black patients and those seen in our urban clinics suggesting the need for improvement in health literacy in these populations. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m.

  • Abstract #1002103: A Rare Case of Pituicytoma

    by Pushyami Mikkilineni, Simon Rebecca

  • Open Access

    Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors

    by Sunil Badami, Sunil Upadhaya, Ravi Kanth Velagapudi, Pushyami Mikkilineni, Ranju Kunwor, Samer Al Hadidi, Ghassan Bachuwa

    Background. We performed meta-analysis to gather more evidence regarding clinical-molecular subgroups associated with better overall survival (OS) in advanced melanoma treated with checkpoint inhibitors. Materials and Methods. We performed a systematic search of PubMed, Scopus, Cochrane Library, and clinical trial.gov. Randomized clinical trials that compared a checkpoint inhibitor (nivolumab or pembrolizumab) with investigator choice chemotherapy or ipilimumab were included in our study. Hazard ratios (HR) and confidence interval (CI) were calculated for progression-free survival (PFS) and OS for each subgroup using generic inverse model along with the random effect method. Results. A total of 6 clinical trials were eligible for the meta-analysis. OS was prolonged in wild BRAF subgroup (HR 0.65, 95% CI 0.49-0.85, p 0.002), Programmed cell death subgroup (PD-1+) (HR 0.57, 95% CI 0.41-0.80, p 0.001), and high lactate dehydrogenase (LDH) level subgroup (HR 0.60, 95% CI 0.38-0.95, p 0.03). Similarly, we found increased OS in eastern cooperative oncology group (ECOG) 1, males and age >65 years subgroups. Conclusions. Checkpoint inhibitors significantly increased OS in patients with wild BRAF, positive PD-1, and high LDH. However, results should be interpreted keeping in mind associated significant heterogeneity. The results of this study should help in designing future clinical trials.